Zee Entertainment valuations are cheap and growth projections have upside risk, CLSA says

Of the 16 analysts who have coverage on Zee Entertainment, seven have a “buy” rating, three have a “hold” rating and six have a “sell” rating.

Of the 16 analysts who have coverage on Zee Entertainment, seven have a “buy” rating, three have a “hold” rating and six have a “sell” rating.

Richard Redoglia, CEO of Matrix Global, explains why oil market volatility has dropped sharply despite tensions in the Middle East, how Iran’s sanctions relief could affect global supply, and why futures markets are signalling lower crude prices ahead.

Jefferies expects the sector to deliver healthy loan growth, easing credit costs and largely range-bound NIMs. While valuations have recovered from the lows seen during the recent geopolitical tensions, they remain broadly around long-term averages.

Vishal Mega Mart is a near “consensus buy” among analysts on Dalal Street as 19 out of the 20 who track the stock, have a “buy” rating on it.

According to UBS, its channel checks indicate that Titan could be headed for another strong growth quarter. It believes jewellery revenue growth of 35-40% remains a realistic possibility, suggesting that the momentum witnessed in the third quarter of FY26 has…

JPMorgan expects the market to reward persistent market share gains and operating leverage which will improve margins going forward. How regulations shapes derivative volumes will be a key inflection point for this sector going forward.

Drew Pettit, Director-US Equity Strategy/ETF Analysis & Strategy Research at Citi expects Brent crude prices to trend lower, while cautioning that a more hawkish Federal Reserve could offset some of the benefits. He also argues that today’s market exuberance, though…

By financial year 2028, Tata Motors CV is aiming for free cash flow to be between 7% to 9% of revenue, while its Return on Capital Employed could jump to 30% to 35% after the Iveco deal.

Government amends FCRA rules for NGOs, tightening foreign funding norms, restricting proselytisation, and mandating detailed disclosures and spending thresholds.

The US Food and Drug Administration (USFDA) has approached Indian pharma manufacturers for ifofamide, a drug used in treating testicular, bladder and lung cancers, as per the Mint report.